30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Year in Review

2014 Revenue: Wright Medical

4Q14 revenue: $83.3MM, +25% (U.S. $62.4MM, +27%; ex-U.S. $20.8MM, +19%)

Foot/Ankle $57.1MM, +34% (Total Ankle +38%)

  • U.S. $46.0MM, +39%
  • Ex-U.S. $11.1MM, +20%

Upper Extremity $6.3MM, -1%

  • U.S. $3.8MM, -14%
  • Ex-U.S. $2.4MM, +27%

Biologics $17.2MM, +10%

  • U.S. $12.1MM, +10%
  • Ex-U.S. $5.1MM, +12%

Other $2.5MM, +14%

  • U.S. $0.4MM, -10%
  • Ex-U.S. $2.0MM, +21%

 

2014 revenue: of $298.0MM, +23% (U.S. $212.0MM, +19%; ex-U.S. $85.9MM, +34%)

Foot/Ankle $195.6MM, +30%

  • U.S. $148.6MM, +29%
  • Ex-U.S. $47.0MM, +34%

Upper Extremity $26.6MM, +8%

  • U.S. $15.3MM, -12%
  • Ex-U.S. $11.3MM, +58%

Biologics $66.0MM, +11%

  • U.S. $45.4MM, +7%
  • Ex-U.S. $20.5MM, +22%

Other Extremities $9.6MM, +34%

  • U.S. $2.6MM, +31%
  • Ex-U.S. $7.0MM, +36%

 

Trained ~450 total ankle physicians in 2014

Augment update: assuming mid-2Q clearance from FDA

INVISION revision ankle likely to be a 2016 product